The IL-23/IL-17 axis is a major focus of spondyloarthritis research, and many pharmaceutical companies are actively working on strategies to block IL-17 in uveitis, AS and related spondyloarthropathies [14,15,36,42]. Here, IL23A is linked to spondyloarthropathy.